Repligen (NASDAQ:RGEN) Releases FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.50-1.58 for the period, compared to the consensus estimate of $1.44. The company issued revenue guidance of $630-639 million, compared to the consensus revenue estimate of $629.61 million. Repligen also updated its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Stock Down 6.2 %

RGEN stock traded down $8.88 during trading on Friday, reaching $133.55. 136,573 shares of the stock were exchanged, compared to its average volume of 657,876. The firm’s 50 day moving average is $141.59 and its 200 day moving average is $144.78. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.48 billion, a P/E ratio of -361.50, a price-to-earnings-growth ratio of 4.36 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 EPS. As a group, research analysts forecast that Repligen will post 1.44 EPS for the current year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Wolfe Research initiated coverage on Repligen in a report on Thursday. They issued a “peer perform” rating for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Wednesday. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.